XARELTO®: Dosing for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients

XARELTO®: Once-daily oral dose for vte risk reduction in acutely ill medical patients both inpatient and outpatient

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*Calculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance; VTE= venous thromboembolism.